Drugs for Myelodysplastic Syndromes
Find financial assistance programs available for myelodysplastic syndrome drugs.
Gleevec (imatinib mesylate) Tablets
Drug company: Novartis
Gleevec is a kinase inhibitor used for the treatment of
patients with myelodysplastic syndromes or myeloproliferative
disease associated with PDGFR gene rearrangements,
as determined by an FDA-approved test.
Novartis’ Patient Assistance NOW Oncology offers 2 financial
assistance programs for patients using Gleevec:
Novartis Oncology Universal Co-pay Program
Eligible patients with private insurance may pay only $10
for a 30-day supply of Gleevec, with a maximum benefit of
$10,630 per 30-day supply up to an annual maximum
benefit of $30,000.
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have
limited or no public or private prescription coverage may be
able to receive Gleevec for free through the Novartis Patient
Assistance Foundation. To be eligible for financial assistance,
the patient must be a US citizen and must provide
proof of income that meets the financial eligibility requirements.
Eligible patients may receive Gleevec for free until
prescription drug coverage becomes available to them.
Inqovi (decitabine + cedazuridine) Tablets
Drug company: Taiho Oncology
Inqovi is a combination of decitabine, a nucleoside metabolic
inhibitor, and cedazuridine, a cytidine deaminase inhibitor,
used for treatment of adults with myelodysplastic syndromes
(MDS), including previously treated and untreated
MDS with refractory types of anemia, and chronic myelomonocytic
leukemia, and intermediate-risk or high-risk MDS.
Taiho Oncology offers 2 financial assistance programs for
patients who have been prescribed Inqovi:
Taiho Oncology Patient Support Co-pay Assistance
Eligible patients who have commercial (or private) insurance
may have a $0 copay per treatment cycle of Inqovi, for
a maximum benefit limit of $6,000 per month and $36,000
Patient Assistance Program
This program offers financial assistance for eligible patients
who are uninsured or underinsured and who have insufficient
financial resources to pay for Inqovi. Patients may receive
Inqovi for free based on assistance, financial, and medical
Revlimid (lenalidomide) Capsules
Drug company: Bristol Myers Squibb
Revlimid is a thalidomide analog used for the treatment of transfusion-dependent anemia caused by low- or intermediate-risk myelodysplastic syndromes that is associated with a deletion 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities.
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:
BMS Oncology Co-Pay Assistance Program
This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Revlimid. Patients pay a $10 copay, while BMS covers the remaining amount, up to $15,000 annually.
Bristol Myers Squibb Patient Assistance Foundation
BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Revlimid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.
Table. Drugs Prescribed for Myelodysplastic Syndromes
- Drug name (generic name)
- Drug company
- Patient support services
Last modified: April 1, 2022